Background Primary cutaneous B-cell lymphoma (PCBCL) is a group of lymphomas the skin containing primary follicle centre (PCFCL) and marginal zone lymphoma/lymphoproliferative disorder (PCMZL), which are indolent, diffuse large lymphoma, leg type (PCDLBCL-LT), aggressive. Objectives To evaluate treatment outcomes between PCBCL subtypes after with rituximab to compare efficacy intralesional agai...

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (iDLBCL/BL) is a newly categorized lymphoma in the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues v4. This lymphoma has characteristics of both DLBCL and BL, morphologically and genetically. We report a case with therapy-resistant iDLBCL/BL, which used to b...

Introduction: Patients with Diffused large B cell lymphoma (DLBCL) who are also co-infected Hepatitis virus (HBV) may experience HBV reactivation during immunochemotherapy which can delay or prematurely terminate anti-tumor treatment. It is usually considered that patients hepatitis surface antigen-positive (HBsAg+) have a higher rate of and poorer prognosis compared resolved infection (HBsAg+/...

Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian targ...

Burkitt's lymphoma is a highly aggressive lymphoma identified and described in the last century by Denis Burkitt in Africa, in areas endemic for malaria. Since its description in African children, it has been recognized outside areas with endemic malaria, frequently also in children as well as among individuals with an underlying immunodeficiency. Since its initial designation as Burkitt's lymp...

Summary This year’s virtual version of the European Society for Medical Oncology (ESMO) presidential sessions included three “late breaking” non-small cell lung cancer (NSCLC) abstracts, discussing strategies adjuvant therapy localized disease and up-front treatment advanced anaplastic lymphoma kinase(ALK)-positive cancer.

introduction: lymphomas as a group rank seventh as the most leading cause of death in cancers. stomach is the most common extra nodal site of primary lymphomas. on the other hand, new information demonstrates that malt lymphoma responds to helicobacter antibiotic therapy. we therefore decided to determine the frequency of distribution of helicobacter pylori infection in primary gastric lymphoma...

Abstract Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during past five years, boasting impressive response rates and durable remissions for patients who previously had no viable options. In this review, we provide a brief historical overview their development. We focus on practical aspects patient’s journey through unique toxicities current b...

Introduction. ?Grey zone Lymphoma?? is associated with various entities. The last published classification of lymphoproliferative neoplasms includes mediastinal grey lymphoma. Precise diagnostic criteria are insufficient and establishing a diagnosis as complex deciding on treatment options. In this article pathologist hematologist discuss issues topic through case presentation literature review...

BACKGROUND & AIMS Combination therapy with infliximab and azathioprine has demonstrated benefit over monotherapy for moderate-to-severe Crohn's disease. Clinical trials and models have not accounted for age-specific risks associated with these therapies, including the risk of immunosuppression-related cancer and infection. After accounting for these risks, the strategy yielding the greatest ben...